



FOR IMMEDIATE RELEASE

ExoBioMed Vascular and PECA Labs® Announce Strategic Development and Manufacturing Agreement for the ExoAqua™ Vascular Graft

Agreement covers product development, testing, regulatory documentation support, manufacturing scale-up and commercial production

UNIONVILLE, Pa. and PITTSBURGH, August 28, 2026 — ExoBioMed Vascular, Inc., a vascular-focused spin-out of ExoBioMed, today announced a strategic collaboration with PECA Labs®, Inc. to advance the ExoAqua™ Vascular Graft.

The collaboration combines ExoBioMed Vascular's proprietary ExoAqua™ Gel technology with PECA Labs' specialized capabilities in polymeric cardiovascular-device design, development, engineering, quality, regulatory and manufacturing capabilities. Under a defined and agreed-to project plan, PECA Labs® will provide product development, testing, technical documentation, validation, and regulatory support services associated with ExoBioMed Vascular's planned U.S. regulatory program.

PECA Labs® contract development and manufacturing unit will also support manufacturing process development and scale-up, including the equipment and instrumentation activities needed to establish commercial manufacturing readiness. The parties intend for PECA Labs® to serve as ExoBioMed Vascular's exclusive commercial manufacturing partner for the product following applicable FDA clearance or approval, with commercial supply to be governed by a definitive supply agreement.

ExoBioMed Vascular is pursuing a staged development and regulatory strategy. The initial program is focused on a 3 mm ID ExoAqua™ vascular graft for peripheral vascular and trauma applications, while the company continues development of smaller-diameter configurations for future vascular indications.

Following advancement of the initial program, ExoBioMed Vascular intends to pursue additional small- and micro-diameter vascular applications, including vascular grafts for coronary artery bypass grafting (CABG). These future applications are expected to require additional preclinical development, clinical investigation and applicable regulatory review.

ExoAqua™ Gel technology is a proprietary, high-water-content biomaterial platform engineered to combine hydration with mechanical integrity through a cross-linked architecture. ExoBioMed Vascular is developing the platform for demanding vascular applications where handling, compliance, hemocompatibility, durability and resistance to kinking are critical design considerations.

"This collaboration establishes a defined execution pathway for the ExoAqua™ Vascular Graft—from product development and regulatory preparation through manufacturing scale-up and commercial supply," said Anthony Merulla, founder and CEO of ExoBioMed Vascular. "PECA Labs brings demonstrated cardiovascular device experience and established development and manufacturing capabilities to the program. Together, our objective is to advance this technology efficiently and responsibly toward clinical and commercial development."



“PECA Labs® has spent years building specialized expertise in polymeric cardiovascular-device design, development and manufacturing through our own cardiovascular programs,” added Doug Bernstein, chief executive officer of PECA Labs®. “This collaboration also reflects our ability to selectively support external cardiovascular device programs where our expertise is a strong fit, and we are pleased to bring that experience and our integrated engineering, testing, quality and manufacturing infrastructure to support ExoBioMed Vascular’s development plan.”

About ExoBioMed Vascular

ExoBioMed Vascular is a vascular-focused spin-out of ExoBioMed created to develop and commercialize next-generation vascular graft technologies based on its proprietary ExoAqua™ Gel technology. The company’s initial program is focused on a 3 mm internal-diameter vascular graft for peripheral vascular and trauma applications. Longer term, ExoBioMed Vascular intends to pursue additional small-diameter and submillimeter vascular applications, including CABG and neurovascular applications, subject to the development, clinical and regulatory requirements applicable to each indication.

About PECA Labs®

PECA Labs® is reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow and last. The company’s proprietary technologies, including its controllably expandable vascular graft and polymeric membrane technologies, are built on a tunable polymer platform designed to enable greater durability, customization, and biocompatibility across cardiovascular implants such as vascular grafts and surgical and transcatheter valves. PECA Labs® develops and manufactures cardiovascular devices through an integrated platform spanning polymer engineering, device development, testing and manufacturing. For more information, visit pecalabs.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding product development, regulatory strategies, manufacturing scale-up, potential indications and commercialization. These statements are subject to technical, regulatory, clinical, manufacturing, contractual and commercial risks and uncertainties, and actual outcomes may differ materially from those anticipated. Investigational applications described in this release have not been cleared or approved by the U.S. Food and Drug Administration unless expressly stated otherwise. Statements regarding ExoAqua™ technology, product characteristics, intended indications and development plans reflect ExoBioMed Vascular’s program and strategy. PECA Labs®’ role is limited to the services described above. PECA Labs® makes no representation regarding the safety, effectiveness, performance or regulatory status of the ExoAqua™ Vascular Graft.

Media Contact

ExoBioMed Vascular

Anthony Merulla, Founder & CEO

anthony@exo-biomed.com

<https://exo-biomed.com/>

PECA Labs

Joe Duraes

Pazanga Health Communications

jduraes@pazangahealth.com

(917) 687-6419

<https://www.pecalabs.com>